Medicxi bankrolls the launch of a pair of biotech twins fo­cused on orex­ins for nar­colep­sy and more

The ven­ture in­vestors at Medicxi are fund­ing a pair of biotech spin­outs from UK-based So­sei Hep­tares, which has been fine tun­ing its ex­per­tise in G pro­tein-cou­pled re­cep­tors for a num­ber of years now.

Medicxi is of­fer­ing €40 mil­lion to kick­start two new com­pa­nies — the twins Orex­ia and In­ex­ia, which will tar­get Orex­in OX1 and OX2 for neu­ro­log­i­cal dis­eases. The Hep­tares sub­sidiary will put its re­searchers to work on the two projects, iden­ti­fy­ing nar­colep­sy as one key dis­ease on the menu.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN